575 related articles for article (PubMed ID: 18474441)
1. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
6. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
7. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells.
Lapillonne H; Konopleva M; Tsao T; Gold D; McQueen T; Sutherland RL; Madden T; Andreeff M
Cancer Res; 2003 Sep; 63(18):5926-39. PubMed ID: 14522919
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
9. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins.
Zi X; Feyes DK; Agarwal R
Clin Cancer Res; 1998 Apr; 4(4):1055-64. PubMed ID: 9563902
[TBL] [Abstract][Full Text] [Related]
10. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T
Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines.
Turturro F; Friday E; Fowler R; Surie D; Welbourne T
Clin Cancer Res; 2004 Oct; 10(20):7022-30. PubMed ID: 15501982
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
Koga H; Harada M; Ohtsubo M; Shishido S; Kumemura H; Hanada S; Taniguchi E; Yamashita K; Kumashiro R; Ueno T; Sata M
Hepatology; 2003 May; 37(5):1086-96. PubMed ID: 12717389
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
Li M; Lee TW; Yim AP; Mok TS; Chen GG
J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
Yin F; Wakino S; Liu Z; Kim S; Hsueh WA; Collins AR; Van Herle AJ; Law RE
Biochem Biophys Res Commun; 2001 Sep; 286(5):916-22. PubMed ID: 11527386
[TBL] [Abstract][Full Text] [Related]
15. Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPARgamma in A549 cells.
Kim HJ; Woo IS; Kang ES; Eun SY; Kim GH; Ham SA; Kim HJ; Lee JH; Chang KC; Kim JH; Lee HT; Seo HG
Biochem Biophys Res Commun; 2006 Oct; 349(2):660-7. PubMed ID: 16945329
[TBL] [Abstract][Full Text] [Related]
16. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells.
Choi EJ; Kim GH
Phytomedicine; 2008 Sep; 15(9):683-90. PubMed ID: 18541420
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
19. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways.
Vanderlaag K; Su Y; Frankel AE; Grage H; Smith R; Khan S; Safe S
Breast Cancer Res Treat; 2008 May; 109(2):273-83. PubMed ID: 17624585
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells.
Laurora S; Pizzimenti S; Briatore F; Fraioli A; Maggio M; Reffo P; Ferretti C; Dianzani MU; Barrera G
J Pharmacol Exp Ther; 2003 Jun; 305(3):932-42. PubMed ID: 12649303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
